Allakos Inc   (ALLK)
Other Ticker:  

Allakos Inc's Customers Performance


ALLK's Source of Revenues

List of ALLK Customers

for the same period Allakos Inc

List of ALLK Customers

Allakos Inc's Comment on Sales, Marketing and Customers

  News about Allakos Inc Contracts

Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Fail to Meet Primary Endpoints: Implications for Allakos' Future Development

In recent years, the field of pharmaceutical sciences has witnessed tremendous progress in the development of novel therapeutics. One such promising candidate was lirentelimab, a drug developed by Allakos Inc., aimed at providing relief for patients suffering from atopic dermatitis and chronic spontaneous urticaria. However, despite initial optimism, the company recently announced that the Phase 2 trials of lirentelimab did not meet their primary endpoints. This article explores the implications of this setback for Allakos Inc., their decision to discontinue further development of lirentelimab, and their strategic focus on alternative clinical development programs.Background:Atopic dermatitis, commonly refer...

ALLK's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Allakos Inc 101.05 0.00 -166.14 149
SUBTOTAL 0.00 0.00 0.00 -


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com